A brutal year for biotech has private investors eyeing bets with less risk and more emphasis on single assets over drug discovery engines, but there’s plenty of optimism to go around in the opening weeks of 2023.
Source: Investors eye less risky bets, shift away from platform biotechs | Fierce Biotech
The 3 Ways Work Can Be Automated | Harvard Business Review
Learning Is a Learned Behavior. Here’s How to Get Better at It. | Harvard Business Review
Why talent acquisition teams need to work closer with L&D
5 Behaviors of Leaders Who Embrace Change | Harvard Business Review"*" indicates required fields
(770) 299-4515
Submit Resume
